FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005958049> ?p ?o ?g. }

• W2005958049 endingPage "18" @default.
• W2005958049 startingPage "18" @default.
• W2005958049 abstract "Background: Fine needle aspiration biopsy (FNAB) is a common and excellent procedure for the evaluation of thyroid lesions that require surgical resection. At times, the FNAB diagnosis can be difficult, particularly of follicular-patterned lesions. Previous studies have shown that some immunohistochemical (IHC) markers may be helpful in establishing more accurate diagnosis. In this study, our goal was to evaluate four of the recently investigated markers in differentiating benign from malignant thyroid nodules on FNABs. Materials and Methods: We performed IHC staining of galectin-3, Ret oncoprotein (Ret), HBME-1, and cytokeratin 19 (CK19), on cell block sections of thyroid FNAB cases that had corresponding surgical resections. They included 44 benign lesions (37 hyperplastic or cellular nodules, HN; and 7 follicular adenomas, FA) and 27 malignant tumors (6 follicular carcinoma, FC; 19 classic papillary carcinoma, PTC; and 2 follicular variant of papillary carcinoma, FVPC). The stains were done according to the standard avidin–biotin–peroxidase method. Results: Statistical analysis showed that immunoexpression was significantly higher in the malignant group for all four markers. The sensitivity for positive expression for all benign lesions versus malignant tumors was as follows: 10/44 (22.7%) versus 25/27 (92.6%) for galectin-3; 14/44 (31.8%) versus 23/27 (85%) for Ret; 12/44 (27.3%) versus 24/27 (88.8%) for HBME-1; and 13/44 (29.5%) versus 23/27 (85%) for CK19. The sensitivity and specificity was highest for galectin-3 (92.6% and 77.3%, respectively) followed by HMBE-1 (88.9% and 72.7%, respectively). When combining the markers' expressions, the panel of galectin-3 + HBME-1 showed the highest sensitivity and specificity (90.7% and 75%, respectively), but this was, however, lower than galectin-3 alone (92.3% and 77.3%, respectively). Conclusion: We conclude that galectin-3 is the best single marker in differentiating benign from malignant thyroid lesions with the highest sensitivity and specificity. The galectin-3 + HBME-1 was the best combination for distinguishing benign from malignant lesions. Because they were the best two independent and combined markers, we recommend the use of the galectin-3 + HBME-1 panel to enhance the diagnostic accuracy of follicular-patterned thyroid lesions on FNABs." @default.
• W2005958049 created "2016-06-24" @default.
• W2005958049 creator A5019682520 @default.
• W2005958049 creator A5020549923 @default.
• W2005958049 creator A5051004445 @default.
• W2005958049 creator A5063670528 @default.
• W2005958049 creator A5073410660 @default.
• W2005958049 creator A5090483140 @default.
• W2005958049 date "2009-09-18" @default.
• W2005958049 modified "2023-09-27" @default.
• W2005958049 title "Differential expression of galectin-3, CK19, HBME1, and Ret oncoprotein in the diagnosis of thyroid neoplasms by fine needle aspiration biopsy" @default.
• W2005958049 cites W1926228846 @default.
• W2005958049 cites W1932946942 @default.
• W2005958049 cites W1966551530 @default.
• W2005958049 cites W1974750835 @default.
• W2005958049 cites W1978050355 @default.
• W2005958049 cites W1984407994 @default.
• W2005958049 cites W1990221732 @default.
• W2005958049 cites W1994445587 @default.
• W2005958049 cites W2011562398 @default.
• W2005958049 cites W2013868768 @default.
• W2005958049 cites W2018838648 @default.
• W2005958049 cites W2020314607 @default.
• W2005958049 cites W2021767367 @default.
• W2005958049 cites W2024290243 @default.
• W2005958049 cites W2028831219 @default.
• W2005958049 cites W2038609896 @default.
• W2005958049 cites W2042679756 @default.
• W2005958049 cites W2045012131 @default.
• W2005958049 cites W2059815238 @default.
• W2005958049 cites W2060471898 @default.
• W2005958049 cites W2061869784 @default.
• W2005958049 cites W2063211982 @default.
• W2005958049 cites W2063583377 @default.
• W2005958049 cites W2092319839 @default.
• W2005958049 cites W2107283570 @default.
• W2005958049 cites W2133075923 @default.
• W2005958049 cites W2135159580 @default.
• W2005958049 cites W2136721607 @default.
• W2005958049 cites W2152759367 @default.
• W2005958049 cites W2168402896 @default.
• W2005958049 cites W2170470342 @default.
• W2005958049 doi "https://doi.org/10.4103/1742-6413.55894" @default.
• W2005958049 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2758025" @default.
• W2005958049 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19826479" @default.
• W2005958049 hasPublicationYear "2009" @default.
• W2005958049 type Work @default.
• W2005958049 sameAs 2005958049 @default.
• W2005958049 citedByCount "43" @default.
• W2005958049 countsByYear W20059580492012 @default.
• W2005958049 countsByYear W20059580492013 @default.
• W2005958049 countsByYear W20059580492014 @default.
• W2005958049 countsByYear W20059580492015 @default.
• W2005958049 countsByYear W20059580492016 @default.
• W2005958049 countsByYear W20059580492017 @default.
• W2005958049 countsByYear W20059580492018 @default.
• W2005958049 countsByYear W20059580492019 @default.
• W2005958049 countsByYear W20059580492021 @default.
• W2005958049 countsByYear W20059580492022 @default.
• W2005958049 countsByYear W20059580492023 @default.
• W2005958049 crossrefType "journal-article" @default.
• W2005958049 hasAuthorship W2005958049A5019682520 @default.
• W2005958049 hasAuthorship W2005958049A5020549923 @default.
• W2005958049 hasAuthorship W2005958049A5051004445 @default.
• W2005958049 hasAuthorship W2005958049A5063670528 @default.
• W2005958049 hasAuthorship W2005958049A5073410660 @default.
• W2005958049 hasAuthorship W2005958049A5090483140 @default.
• W2005958049 hasBestOaLocation W20059580491 @default.
• W2005958049 hasConcept C126322002 @default.
• W2005958049 hasConcept C142724271 @default.
• W2005958049 hasConcept C194495517 @default.
• W2005958049 hasConcept C204232928 @default.
• W2005958049 hasConcept C2775934546 @default.
• W2005958049 hasConcept C2776170712 @default.
• W2005958049 hasConcept C2779012181 @default.
• W2005958049 hasConcept C2779022025 @default.
• W2005958049 hasConcept C2779399171 @default.
• W2005958049 hasConcept C2780801072 @default.
• W2005958049 hasConcept C2993294228 @default.
• W2005958049 hasConcept C526584372 @default.
• W2005958049 hasConcept C71924100 @default.
• W2005958049 hasConceptScore W2005958049C126322002 @default.
• W2005958049 hasConceptScore W2005958049C142724271 @default.
• W2005958049 hasConceptScore W2005958049C194495517 @default.
• W2005958049 hasConceptScore W2005958049C204232928 @default.
• W2005958049 hasConceptScore W2005958049C2775934546 @default.
• W2005958049 hasConceptScore W2005958049C2776170712 @default.
• W2005958049 hasConceptScore W2005958049C2779012181 @default.
• W2005958049 hasConceptScore W2005958049C2779022025 @default.
• W2005958049 hasConceptScore W2005958049C2779399171 @default.
• W2005958049 hasConceptScore W2005958049C2780801072 @default.
• W2005958049 hasConceptScore W2005958049C2993294228 @default.
• W2005958049 hasConceptScore W2005958049C526584372 @default.
• W2005958049 hasConceptScore W2005958049C71924100 @default.
• W2005958049 hasLocation W20059580491 @default.
• W2005958049 hasLocation W20059580492 @default.
• W2005958049 hasLocation W20059580493 @default.
• W2005958049 hasLocation W20059580494 @default.

• next